Formed in 2019, The Amyloidosis Forum has been developed through a public-private partnership between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA). The overarching goal of the Forum is to optimize innovation and accelerate the advancement of new therapeutics by addressing scientific gaps and needs through the conduct of mutually beneficial scientific activities in the precompetitive domain that aid in the scientific evaluation of the efficacy and safety of new therapies.
Registration Open!
Join us in-person at FDA’s White Oak Campus on September 30, 2026.
Register today to reserve your spot!
Unable to attend in-person? No worries! Join us virtually on the day of the event, or watch a recording of the meeting available afterward, so you won’t miss any of the discussions.